Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 89 3-Year EPS without NRI Growth Rate is 10.40% as of Feb. 2026, which is 24% below its 10-year median of 13.60. GuruFocus rates CSMYF with a GF Score™ of 89/100 and a GF Value™ of $51.94 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 507 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks worse than 51.68% on this metric.
During the past 12 months, COSMOS Pharmaceutical's average EPS without NRI Growth Rate was 2.50% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 10.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 6.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 8.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of COSMOS Pharmaceutical was 31.20% per year. The lowest was -0.50% per year. And the median was 13.60% per year.
COSMOS Pharmaceutical (OTCPK:CSMYF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
COSMOS Pharmaceutical 3-Year EPS without NRI Growth Rate Related Terms
COSMOS Pharmaceutical 3-Year EPS without NRI Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's 3-Year EPS without NRI Growth Rate falls into.
COSMOS Pharmaceutical 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 10.40% mean?
COSMOS Pharmaceutical (CSMYF) has a 3-Year EPS without NRI Growth Rate of 10.40% as of Feb. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for COSMOS Pharmaceutical and its competitors. This is 24% below median its historical median of 13.60. According to the industry distribution chart, COSMOS Pharmaceutical ranks #262 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 51.7%.
Is COSMOS Pharmaceutical's 3-Year EPS without NRI Growth Rate too high?
COSMOS Pharmaceutical's current 3-Year EPS without NRI Growth Rate of 10.40% is 24% below median its 10-year median of 13.60. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.10. COSMOS Pharmaceutical's value of 10.40% is 6.3% below this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #262 out of 507 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's 3-Year EPS without NRI Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #262 out of 507 companies for 3-Year EPS without NRI Growth Rate. This places COSMOS Pharmaceutical in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.10. COSMOS Pharmaceutical's value of 10.40% is 6.3% below this benchmark. While the company's 10-year median is 13.60 vs. the industry median of 11.10, COSMOS Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.10, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current 3-Year EPS without NRI Growth Rate of 10.40% is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for COSMOS Pharmaceutical and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current 3-Year EPS without NRI Growth Rate is 10.40%, which is 24% below median its own 10-year median of 13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.94, compared to a current price of $37.06 — trading 28.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 10.40%, which is 24% below median its 10-year median of 13.60 and 6.3% below the Healthcare Providers & Services industry median of 11.10. COSMOS Pharmaceutical's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current 3-Year EPS without NRI Growth Rate is 10.40% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 28.6% below its estimated GF Value™ of $51.94.
GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.
Key valuation signals for CSMYF:
3-Year EPS without NRI Growth Rate: 10.40% (24% below median its 10-year median of 13.60)
GF Value™: $51.94 vs. price of $37.06 (28.6% below fair value)
Industry Position: 6.3% below the Healthcare Providers & Services median (#262 of 507)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
89GF Score
Get the complete analysis for CSMYF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
